Cargando…

Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study

There is growing interest in Phase I dose-finding studies studying several doses of more than one agent simultaneously. A number of combination dose-finding designs were recently proposed to guide escalation/de-escalation decisions during the trials. The majority of these proposals are model-based:...

Descripción completa

Detalles Bibliográficos
Autores principales: Mozgunov, Pavel, Knight, Rochelle, Barnett, Helen, Jaki, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796482/
https://www.ncbi.nlm.nih.gov/pubmed/33466469
http://dx.doi.org/10.3390/ijerph18010345
_version_ 1783634692736548864
author Mozgunov, Pavel
Knight, Rochelle
Barnett, Helen
Jaki, Thomas
author_facet Mozgunov, Pavel
Knight, Rochelle
Barnett, Helen
Jaki, Thomas
author_sort Mozgunov, Pavel
collection PubMed
description There is growing interest in Phase I dose-finding studies studying several doses of more than one agent simultaneously. A number of combination dose-finding designs were recently proposed to guide escalation/de-escalation decisions during the trials. The majority of these proposals are model-based: a parametric combination-toxicity relationship is fitted as data accumulates. Various parameter shapes were considered but the unifying theme for many of these is that typically between 4 and 6 parameters are to be estimated. While more parameters allow for more flexible modelling of the combination-toxicity relationship, this is a challenging estimation problem given the typically small sample size in Phase I trials of between 20 and 60 patients. These concerns gave raise to an ongoing debate whether including more parameters into combination-toxicity model leads to more accurate combination selection. In this work, we extensively study two variants of a 4-parameter logistic model with reduced number of parameters to investigate the effect of modelling assumptions. A framework to calibrate the prior distributions for a given parametric model is proposed to allow for fair comparisons. Via a comprehensive simulation study, we have found that the inclusion of the interaction parameter between two compounds does not provide any benefit in terms of the accuracy of selection, on average, but is found to result in fewer patients allocated to the target combination during the trial.
format Online
Article
Text
id pubmed-7796482
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77964822021-01-10 Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study Mozgunov, Pavel Knight, Rochelle Barnett, Helen Jaki, Thomas Int J Environ Res Public Health Article There is growing interest in Phase I dose-finding studies studying several doses of more than one agent simultaneously. A number of combination dose-finding designs were recently proposed to guide escalation/de-escalation decisions during the trials. The majority of these proposals are model-based: a parametric combination-toxicity relationship is fitted as data accumulates. Various parameter shapes were considered but the unifying theme for many of these is that typically between 4 and 6 parameters are to be estimated. While more parameters allow for more flexible modelling of the combination-toxicity relationship, this is a challenging estimation problem given the typically small sample size in Phase I trials of between 20 and 60 patients. These concerns gave raise to an ongoing debate whether including more parameters into combination-toxicity model leads to more accurate combination selection. In this work, we extensively study two variants of a 4-parameter logistic model with reduced number of parameters to investigate the effect of modelling assumptions. A framework to calibrate the prior distributions for a given parametric model is proposed to allow for fair comparisons. Via a comprehensive simulation study, we have found that the inclusion of the interaction parameter between two compounds does not provide any benefit in terms of the accuracy of selection, on average, but is found to result in fewer patients allocated to the target combination during the trial. MDPI 2021-01-05 2021-01 /pmc/articles/PMC7796482/ /pubmed/33466469 http://dx.doi.org/10.3390/ijerph18010345 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mozgunov, Pavel
Knight, Rochelle
Barnett, Helen
Jaki, Thomas
Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study
title Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study
title_full Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study
title_fullStr Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study
title_full_unstemmed Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study
title_short Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study
title_sort using an interaction parameter in model-based phase i trials for combination treatments? a simulation study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796482/
https://www.ncbi.nlm.nih.gov/pubmed/33466469
http://dx.doi.org/10.3390/ijerph18010345
work_keys_str_mv AT mozgunovpavel usinganinteractionparameterinmodelbasedphaseitrialsforcombinationtreatmentsasimulationstudy
AT knightrochelle usinganinteractionparameterinmodelbasedphaseitrialsforcombinationtreatmentsasimulationstudy
AT barnetthelen usinganinteractionparameterinmodelbasedphaseitrialsforcombinationtreatmentsasimulationstudy
AT jakithomas usinganinteractionparameterinmodelbasedphaseitrialsforcombinationtreatmentsasimulationstudy